Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors

Hollebecque A.Chung H.C.Miguel M.J.D.Italiano A.MacHiels J.-P.CHIA-CHI LINDhani N.C.Peeters M.Moreno V.Su W.-C.Chow K.H.Galvao V.R.Carlse M.Yu D.Szpurka A.M.Zhao Y.Schmidt S.L.Gandhi L.Xu X.Bang Y.-J.2022-09-152022-09-1520211078-0432https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120483182&doi=10.1158%2f1078-0432.CCR-21-0261&partnerID=40&md5=950714ed308d994672ee67bc26f80f6fhttps://scholars.lib.ntu.edu.tw/handle/123456789/620209[SDGs]SDG3Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumorsjournal article10.1158/1078-0432.CCR-21-0261344655992-s2.0-85120483182